Indoximod
As of the edition of 20 October 2026, Indoximod is a small molecule: stopped in 2021; acts on MLST8, MTOR and RPTOR.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2021
- Kind
- Small molecule
- Registered trials
- 16, 3 stopped early
- Disease areas
- Cancer; Skin and connective tissue; Nervous system; Digestive system; Hormones; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 1 |
| Phase 1 | 7 | 5 | 1 | 1 |
| Phase 2 | 8 | 6 | 1 | 1 |
| All trials | 16 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| NewLink Genetics | Lead sponsor of trials | 2013 to now |